Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 + cisplatin + pucotenlimab as neoadjuvant and adjuvant therapy in stage IVB oral/HPV-negative oropharyngeal squamous cell carcinoma
ChiCTR2600128666Phase 2Not yet recruiting
- Sponsor
- Hospital of Stomatology Wuhan University
- Start
- Jul 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vibecotamab, cisplatin and pucotenlimab in Oral Mucosal Carcinoma and oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Hospital of Stomatology Wuhan University. Primary endpoint: Objective Response Rate (ORR). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
vibecotamabcisplatinpucotenlimab
03
Conditions
Oral Mucosal Carcinomaoropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on ChiCTR2600128666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128666.